In a report released yesterday, Akash Tewari from Jefferies maintained a Buy rating on Eli Lilly & Co (LLY – Research Report), with a price ...

When investors are paying such high price tags for a stock, expectations are high, and any kind of miss can result in a steep ...

Sales of Eli Lilly's lead drug, tirzepatide, which it markets as Zepbound for weight loss and Mounjaro for diabetes, leapt up to a combined $5.4 billion in the fourth quarter. That's some amazing ...

Intended for early-stage patients with mild cognitive impairment, annual sales of the monthly infusion are expected to top out above $7 billion. At recent prices, you can buy shares of Eli Lilly ...

Eli Lilly (NYSE: LLY) began a roll in late 2020 that lasted almost four years. During that time, it became the world's ...

Eli Lilly has revised its revenue forecast for 2024 after seeing weaker-than-expected growth for its diabetes and obesity therapies – but still said sales rose ... Lilly's share price, even ...

Middle Tennessee's tight housing market appears to be loosening, with increasing home sales and an uptick in for-sale properties, according to new 2024 data. Greater Nashville Realtors recently ...

GLP-1 drugs have become all the rage for weight loss, with sales for drugs like Novo Nordisk's Ozempic and Eli Lilly's (NYSE: LLY) Mounjaro skyrocketing over the past year. However, Eli Lilly ...

We recently compiled a list of the 15 Best Large-Cap Value Stocks to Buy in 2025. In this article, we are going to take a ...

GLP-1 drugs have become all the rage for weight loss, with sales for drugs like Novo ... From a valuation perspective, Lilly trades at a forward price-to-earnings (P/E) of 25.4 times 2025 analyst ...

CMS monitors prices and may adjust them over time. The process targets high-cost, brand-name drugs without competition. Shares of Eli Lilly were already in an intermediate-term decline before the ...